Evidence map›Paper›PMID 40241541›Full record

ArticleHaematologica2025

A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in

Patrice Chevallier, Anne Thiebaut, Sylvie François, Sylvain Chantepie, Marie-Thérèse Rubio, Hélène Labussiere-Wallet, Eolia Brissot, Natacha Maillard, Anne Huynh, Valérie Coiteux and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Patrice ChevallierHematology Department, Nantes University Hospital, Nantes, France; INSERM UMR1232, CRCINA IRS-UN, University of Nantes. patrice.chevallier@chu-nantes.fr.
Anne ThiebautHematology Department, Grenoble University Hospital, Grenoble.
Sylvie FrançoisHematology Department, Angers University Hospital, Angers.
Sylvain ChantepieHematology Department, Caen University Hospital, Caen.
Marie-Thérèse RubioHematology Department, Nancy University Hospital, Nancy.
Hélène Labussiere-WalletHematology Department, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite.
Eolia BrissotHematology Department, Hôpital St-Antoine, AP-HP, Paris.
Natacha MaillardHematology Department, Poitiers University Hospital, Poitiers.
Anne HuynhHematology Department, IUCT Oncopole, Toulouse.
Valérie CoiteuxHematology Department, Lille University Hospital, Lille.
Maxime JullienHematology Department, Nantes University Hospital, Nantes.
Alice GarnierHematology Department, Nantes University Hospital, Nantes.
Amandine Le BourgeoisHematology Department, Nantes University Hospital, Nantes.
Pierre PeterlinHematology Department, Nantes University Hospital, Nantes.
Thierry GuillaumeHematology Department, Nantes University Hospital, Nantes, France; INSERM UMR1232, CRCINA IRS-UN, University of Nantes.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40241541
PMCPMC12485311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.